West Pharmaceutical Services reported a solid Q3 with revenue of $805M and adj. EPS of $1.96, beating expectations and prompting a full-year guidance raise. Management highlighted accelerating demand in HVP components, driven by GLP-1 elastomers, Annex 1 upgrades, and biologics normalization. 2026 outlook includes a $40M headwind from a CGM contract exit but offset by $20M in new drug-handling revenue and continued margin expansion. Q3 revenue $805M (organic +5%), adj. EPS $1.96, above guidance.
Buzzberg 분석Raised FY25 guidance on revenue and EPSWest Pharmaceutical Services reported a solid Q3 with revenue of $805M and adj. EPS of $1.96, beating expectations and prompting a full-year guidance raise. Management highlighted accelerating demand in HVP components, driven by GLP-1 elastomers, Annex 1 upgrades, and biologics normalization. 2026 outlook includes a $40M headwind from a CGM contract exit but offset by $20M in new drug-handling revenue and continued margin expansion. Q3 revenue $805M (organic +5%), adj. EPS $1.96, above guidance.전체 분석 보기분석 접기
West Pharmaceutical Services reported a solid Q3 with revenue of $805M and adj. EPS of $1.96, beating expectations and prompting a full-year guidance raise. Management highlighted accelerating demand in HVP components, driven by GLP-1 elastomers, Annex 1 upgrades, and biologics normalization. 2026 outlook includes a $40M headwind from a CGM contract exit but offset by $20M in new drug-handling revenue and continued margin expansion. Q3 revenue $805M (organic +5%), adj. EPS $1.96, above guidance.
HVP components grew 13.3% organic, led by GLP-1 (now 9% of total sales), Annex 1 (200bps growth in 2025), and biologics.
Full-year 2025 revenue guidance raised to $3.06–3.07B, adj. EPS to $7.06–7.11.
SmartDose automation on track for early 2026; profitability improving quarter by quarter.
Revenue$0.8043B
reported
EPS$1.96
reported
Gross margin36.49%
reported
Op margin21.6%
reported
이번 분기에 달라진 점
01
Guidance
Raised FY25 guidance on revenue and EPS
Guidance · revenue to $3.065B
02
Demand
HVP components grow 13% organically in Q3
Management expressed confidence in improving business momentum, raised guidance, and highlighted strong growth drivers like GLP-1s and Annex 1 upgrades, while acknowledging some near-term headwinds.
03
Demand
Annex 1 upgrade contribution raised to 200 bps
HVP components grow 13% organically in Q3. Management expressed confidence in improving business momentum, raised guidance, and highlighted strong growth drivers like GLP-1s and Annex 1 upgrades, while acknowledging some near-term headwinds.
04
Demand
GLP-1 elastomers now 9% of total company sales
HVP components grow 13% organically in Q3. Management expressed confidence in improving business momentum, raised guidance, and highlighted strong growth drivers like GLP-1s and Annex 1 upgrades, while acknowledging some near-term headwinds.
수요 및 자본지출
수요
수주 및 전환
HVP components grow 13% organically in Q3. Management expressed confidence in improving business momentum, raised guidance, and highlighted strong growth drivers like GLP-1s and Annex 1 upgrades, while acknowledging some near-term headwinds.
자본지출
투자 및 생산능력
Management indicated that capital expenditures are trending down, with year-to-date investment of $210 million and full-year expectation of $275 million, and they expect to return to the 6-8% of sales corridor for CapEx, heavily weighted toward high-value product components. They also mentioned ongoing investments in capacity expansion at the German HVP site and automated lines for SmartDose.
톤 · Confident
Management expressed confidence in improving business momentum, raised guidance, and highlighted strong growth drivers like GLP-1s and Annex 1 upgrades, while acknowledging some near-term headwinds.
공급망 알파
A1
GLP-1 elastomers now 9% of total sales (vs mid-single-digits in 2024) and growing faster than end-market script data, driven by vial usage, generics, and clinical-trial demand.
Annex 1 upgrade projects (375 ongoing) are now expected to contribute 200bps of growth in 2025, up from the prior 150bps expectation, indicating accelerating conversion of standard components to high-value products.
“we anticipate Annex 1 and related HPP upgrades to deliver 200 basis points of growth this year, up from our previous expectation of 150 basis points.”
SmartDose 3.5 automation is on track for early 2026 go-live, improving profitability each quarter, while management continues to evaluate options to maximize value of the business.
“we remain on track to go live with automation in early 2026, even as we continue to evaluate options to maximize the value of this business.”
GLP-1 elastomers now 9% of total sales (vs mid-single-digits in 2024) and growing faster than end-market script data, driven by vial usage, generics, and clinical-trial demand. — West is benefiting disproportionately as GLP‑1 drugmakers expand vial presentations and pipeline molecules, implying higher-than-expected component demand for Lilly and Novo Nordisk.